Novocure Ltd (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 31,132 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $21.02, for a total value of $654,394.64. Following the completion of the transaction, the chief financial officer now directly owns 240,210 shares in the company, valued at $5,049,214.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Wilhelmus Cm Groenhuysen also recently made the following trade(s):
- On Thursday, January 4th, Wilhelmus Cm Groenhuysen sold 28,868 shares of Novocure stock. The shares were sold at an average price of $21.03, for a total value of $607,094.04.
Novocure Ltd (NVCR) opened at $21.70 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.90 and a quick ratio of 5.30. Novocure Ltd has a 1 year low of $6.00 and a 1 year high of $22.90.
Novocure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. The company had revenue of $50.10 million for the quarter, compared to the consensus estimate of $43.45 million. Novocure had a negative return on equity of 57.68% and a negative net margin of 47.45%. The company’s revenue for the quarter was up 130.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.39) EPS. equities analysts anticipate that Novocure Ltd will post -0.65 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of NVCR. Crow Point Partners LLC acquired a new stake in shares of Novocure during the 4th quarter worth approximately $120,000. BNP Paribas Arbitrage SA grew its holdings in shares of Novocure by 792.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock worth $125,000 after purchasing an additional 6,419 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Novocure during the 3rd quarter worth approximately $212,000. TIAA FSB acquired a new stake in shares of Novocure during the 2nd quarter worth approximately $238,000. Finally, Legal & General Group Plc grew its holdings in shares of Novocure by 8.5% during the 2nd quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 1,092 shares in the last quarter. 41.53% of the stock is currently owned by institutional investors.
A number of research analysts recently weighed in on NVCR shares. Wedbush reissued an “outperform” rating and issued a $25.00 price objective (down from $29.00) on shares of Novocure in a research note on Friday, October 27th. Zacks Investment Research raised Novocure from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, October 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novocure in a research report on Monday, November 20th. Mizuho reaffirmed a “buy” rating and issued a $25.00 price target on shares of Novocure in a research report on Friday, December 1st. Finally, ValuEngine raised Novocure from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Novocure presently has an average rating of “Buy” and an average price target of $21.13.
WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/insider-selling-novocure-ltd-nvcr-cfo-sells-654394-64-in-stock.html.
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.